These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 23662021)

  • 21. Acarbose Add-on Therapy in Patients with Type 2 Diabetes Mellitus with Metformin and Sitagliptin Failure: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study.
    Yang HK; Lee SH; Shin J; Choi YH; Ahn YB; Lee BW; Rhee EJ; Min KW; Yoon KH
    Diabetes Metab J; 2019 Jun; 43(3):287-301. PubMed ID: 30604599
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes.
    Betteridge DJ; Vergès B
    Diabetologia; 2005 Dec; 48(12):2477-81. PubMed ID: 16283239
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vildagliptin efficacy in combination with metformin among Jordanian patients with type 2 diabetes mellitus inadequately controlled with metformin.
    Al Omari M; Khader Y; Dauod AS; Beni Yonis OA; Khassawneh AH
    J Drug Assess; 2016; 5(1):29-33. PubMed ID: 27994943
    [No Abstract]   [Full Text] [Related]  

  • 24. Short and Long Term Effects of a DPP-4 Inhibitor Versus Bedtime NPH Insulin as ADD-ON Therapy in Patients with Type 2 Diabetes.
    da Silva GM; Nogueira KC; Fukui RT; Correia MR; Dos Santos RF; da Silva ME
    Curr Pharm Des; 2016; 22(44):6716-6721. PubMed ID: 27928958
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with sitagliptin monotherapy.
    Fouqueray P; Pirags V; Diamant M; Schernthaner G; Lebovitz HE; Inzucchi SE; Bailey CJ
    Diabetes Care; 2014 Jul; 37(7):1924-30. PubMed ID: 24722500
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of fixed dose combination of Sitagliptin, metformin, and pioglitazone in type 2 Diabetes (IMPACT study): a randomized controlled trial.
    Aashish M; Arindam N; Siddiqi SS; Bhosle D; Mallikarjuna VJ; Amol D; Sanket S; Omkar G; Parth P; Dhruvi H; Durga P; Pradeep D; Suresh K; Vaishali P; Mayura C; Indraneel B; Jayashri S; Arif F; Raghavendra SK; Deepak V; Ravindra T; Shaishav B; Vijay G; Khan K; Mahajani VV; Sharma AD; Mayabhate M; Pawar RR; Aiwale AS; Vinayaka S
    Clin Diabetes Endocrinol; 2024 Feb; 10(1):3. PubMed ID: 38336931
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of Vildagliptin and Pioglitazone in Korean Patients with Type 2 Diabetes Inadequately Controlled with Metformin.
    Kim JH; Kim SS; Baek HS; Lee IK; Chung DJ; Sohn HS; Bae HY; Kim MK; Park JH; Choi YS; Kim YI; Hahm JR; Lee CW; Jo SR; Park MK; Lee KJ; Kim IJ
    Diabetes Metab J; 2016 Jun; 40(3):230-9. PubMed ID: 27098505
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.
    DeFronzo RA; Burant CF; Fleck P; Wilson C; Mekki Q; Pratley RE
    J Clin Endocrinol Metab; 2012 May; 97(5):1615-22. PubMed ID: 22419732
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term efficacy of sitagliptin as either monotherapy or add-on therapy to metformin: improvement in glycemic control over 2 years in patients with type 2 diabetes.
    Katzeff HL; Williams-Herman D; Xu L; Golm GT; Wang H; Dong Q; Johnson JR; O'Neill EA; Kaufman KD; Engel SS; Goldstein BJ
    Curr Med Res Opin; 2015 Jun; 31(6):1071-7. PubMed ID: 25850968
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of Sitagliptin
    Hematyar J; Rashidi H; Zakerkish M; Payami SP; Ghaderian SB
    Maedica (Bucur); 2022 Dec; 17(4):762-770. PubMed ID: 36818268
    [No Abstract]   [Full Text] [Related]  

  • 31. A Comparison of the Effects of Empagliflozin and Sitagliptin, When Combined With Metformin, on Lipid Levels in Patients with Type 2 Diabetes: A Clinical Investigation.
    Ahmed M; Saeed A; Khan MZ; Javaid SZ; Aslam F; Dar SI
    Cureus; 2023 Sep; 15(9):e44709. PubMed ID: 37809225
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of adding pioglitazone or sitagliptin to patients with type 2 diabetes insufficiently controlled with metformin and a sulfonylurea.
    Liu SC; Chien KL; Wang CH; Chen WC; Leung CH
    Endocr Pract; 2013; 19(6):980-8. PubMed ID: 23807528
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy, Safety and Treatment Satisfaction of Glimepiride vs Sitagliptin in Combination with Metformin in Type 2 Diabetes Mellitus.
    Kumar S; Pathak AK; Saikia D; Kumar A
    J Clin Diagn Res; 2015 Dec; 9(12):FC07-10. PubMed ID: 26816909
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sitagliptin/Metformin Versus Insulin Glargine Combined With Metformin in Obese Subjects With Newly Diagnosed Type 2 Diabetes.
    Ji M; Xia L; Cao J; Zou D
    Medicine (Baltimore); 2016 Mar; 95(11):e2961. PubMed ID: 26986104
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low-dose glimepiride with sitagliptin improves glycemic control without dose-dependency in patients with type 2 diabetes inadequately controlled on high-dose glimepiride.
    Umayahara R; Yonemoto T; Kyou C; Morishita K; Ogawa T; Taguchi Y; Inoue T
    Endocr J; 2014; 61(12):1163-70. PubMed ID: 25168659
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative genotoxic and cytotoxic effects of the oral antidiabetic drugs sitagliptin, rosiglitazone, and pioglitazone in patients with type-2 diabetes: a cross-sectional, observational pilot study.
    Oz Gul O; Cinkilic N; Gul CB; Cander S; Vatan O; Ersoy C; Yılmaz D; Tuncel E
    Mutat Res; 2013 Sep; 757(1):31-5. PubMed ID: 23859957
    [TBL] [Abstract][Full Text] [Related]  

  • 37. One-year real-life efficacy of sitagliptin revealed importance of concomitant pioglitazone use in Japanese patients with type 2 diabetes mellitus.
    Suzuki A; Yoshimura N; Mashimo Y; Numakura M; Fujimaki Y; Maeda T; Ishikawa T; Fujimori S; Eto K
    Diabetes Metab Syndr; 2013; 7(3):143-7. PubMed ID: 23953179
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A review of sitagliptin with special emphasis on its use in moderate to severe renal impairment.
    Eligar VS; Bain SC
    Drug Des Devel Ther; 2013; 7():893-903. PubMed ID: 24039399
    [TBL] [Abstract][Full Text] [Related]  

  • 39. First treatment of a child suffering from severe ischemic cardiomyopathy with G-CSF and sitagliptin.
    Zaruba MM; Hiergeist L; Mechea A; Kozlik-Feldmann R; Theisen D; Netz H; Franz WM
    Int J Cardiol; 2013 Dec; 170(2):e41-2. PubMed ID: 24239099
    [No Abstract]   [Full Text] [Related]  

  • 40. Additive postprandial glucose-lowering effects of mitiglinide and sitagliptin in patients with type 2 diabetes mellitus.
    Jung JA; Kaku K; Kim JH; Kim JR; Ko JW; Lee SY; Huh W
    Adv Ther; 2013 Nov; 30(11):1018-29. PubMed ID: 24249434
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.